Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486272 | 0.81 | KIF11 (0.40) | NPC1NFKB1MAPK1RAB9ANFKB2 | |
| SCHEMBL17486143 | 0.80 | DGAT1 (0.50) | BACE1 | |
| SCHEMBL15614860 | 0.79 | BACE1 (0.46) | BACE1 | |
| SCHEMBL17486216 | 0.79 | MAPK1 (0.37) | BACE1NPC1NFKB1MAPK1RAB9A | |
| SCHEMBL17477823 | 0.77 | NPC1 (0.38) | BACE1NPC1NFKB1MAPK1RAB9A | |
| SCHEMBL17486110 | 0.75 | NPC1 (0.36) | BACE1NPC1RAB9AL3MBTL1 | |
| SCHEMBL17486120 | 0.75 | NPC1 (0.36) | BACE1NPC1NFKB1MAPK1RAB9A | |
| SCHEMBL15854450 | 0.73 | NPC1 (0.37) | BACE1NPC1NFKB1MAPK1RAB9A | |
| SCHEMBL20007152 | 0.73 | NPC1 (0.37) | BACE1NPC1NFKB1MAPK1RAB9A | |
| SCHEMBL18015415 | 0.73 | NPC1 (0.37) | BACE1NPC1NFKB1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | BACE1 2807/4885NPC1 3516/4885NFKB1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.